Wholesale Linezolid Pharmaceutical Intermedaites Linezolid

• Customization: Available
• Powder: Yes
• Customized: Negotiable
• Model NO.: QS-linezolid
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Product Name: Linezolid
• CAS No.: 165800-03-3
• Molecular Formula: C16h20fn3o4
• Molecular Weight: 337.35 G/Mol
• Appearance: White to off-White Crystalline Powder
• Identification (HPLC): Retention Time Matches Reference Standard
• Purity (HPLC): 98.0% - 102.0% (W/W)
• Any Individual Impurity: ≤ 0.5%
• Total Impurities: ≤ 2.0%
• Heavy Metals: ≤ 20 Ppm
• Residual Solvents (Gc): Meets Ich Q3c Limits (If Applicable)
• Melting Point: 176°c - 180°c
• Microbial Limits: Total Aerobic Count ≤ 1000 Cfu/G
• Endotoxins (Lal Test): ≤ 0.5 EU/Mg (If Applicable)
• Specific: COA
• Transport Package: Negotiable
• Specification: >99%
• Trademark: QS
• Origin: Xian
• Production Capacity: 1500

Product Description

Wholesale linezolid Pharmaceutical Intermedaites linezolid 

Product Description

Product Details

Product Name	Linezolid
Appearance	White to off-white crystalline powder
Assay	99%
MF	C16H20FN3O4
MW	337.35 g/mol

LinezolidZyvox (U-100766, PNU-100766, linezolidone, linezolid, morpholinone, morpholinone) is a novel synthetic antibiotic of the azolidone class, developed and produced by Pharmacia&Upiohn (acquired by  in the United States. The drug was approved by the FDA on April 18, 2000 This product is the first drug approved by Chemicalbook for the treatment of methicillin-resistant Staphylococcus aureus infection in the United States in 40 years. LinezolidZyvox (U-100766, PNU-100766, linezolidone, linezolid, morpholinone, morpholinone) was launched in China in September 2007. It is a new type of synthetic antibiotic of the azolidone class developed and produced by Pharmacia&Upiohn (now acquired . The US FDA approved the drug for market on April 18, 2000 This product is the first drug approved by Chemicalbook for the treatment of methicillin-resistant Staphylococcus aureus infection in the United States in 40 years. It was launched in China in September 2007 and belongs to the Class B drug of medical insurance. Linezolid is active against most Gram positive bacteria that cause diseases, including Streptococcus, Vancomycin resistant Enterococcus (VRE), and Methicillin resistant Staphylococcus aureus (MRSA). It is used to treat skin infections and pneumonia, but may be used for other infections, such as drug-resistant tuberculosis. Linezolid is active against most Gram positive bacteria that cause disease, including streptococcus, vancomycin resistant enterococci (VRE), and methicillin-resistant Staphylococcus aureus (MRSA). It is used to treat skin infections and pneumonia, but may be used for other infections, such as drug-resistant tuberculosis.

Application&Function

Zyvoxid is used to treat the following infections caused by specific microbial sensitive strains:
1. Infections caused by vancomycin resistant Enterococcus faecium, including concurrent bacteremia;
2. Hospital acquired pneumonia (HAP), caused by Staphylococcus aureus (methicillin-resistant or methicillin-resistant bacterial beads) or Streptococcus pneumoniae (including multidrug-resistant strains [mdrsp]). If it is confirmed or suspected that there is a Gram negative pathogenic bacterial infection, it is necessary to use anti Gram negative bacterial drugs in combination clinically;
3. Complicated skin or skin soft tissue infection (ssti), including diabetes foot infection without osteomyelitis, is caused by Staphylococcus aureus (methicillin sensitive or methicillin resistant beads), Streptococcus pyogenes or Streptococcus anuricus. There is currently no research on the use of linezolid for the treatment of bedsores.
Linalidomide should only be used to treat complex skin or skin soft tissue infections when microbiological tests show sensitive Gram positive bacterial infections. If it is confirmed or suspected that there is a simultaneous infection of Gram negative pathogenic bacteria, linezolid should only be used when there are no other effective treatment measures, and anti Gram negative bacteria drugs must also be used in combination;
4. Non complex skin or skin soft tissue infections caused by Staphylococcus aureus (only methicillin-resistant bacterial beads);
Community acquired pneumonia (CAP) and associated bacteremia are caused by Streptococcus pneumoniae (including multidrug-resistant strains [mdrsp]) or Staphylococcus aureus (only methicillin-resistant bacterial beads).

Specification

ABOUT US